Related Experiment Video
Updated: Oct 25, 2025
Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
Inflammation in COVID-19: from pathogenesis to treatment
1Faculty of Medicine, SEGi University No. 9 Jalan Teknologi, Taman Sains Selangor, Kota Damansara, PJU 5, 47810 Petaling Jaya, Selangor, Malaysia.
Insights
Inflammation is a key feature of coronavirus disease 2019 (COVID-19), potentially leading to severe outcomes. This review examines therapeutic strategies targeting inflammation and the immune system to treat COVID-19.
Area of Science:
- Immunology
- Infectious Diseases
- Pathophysiology
Background:
- Coronavirus disease 2019 (COVID-19) became a global pandemic in March 2020.
- Over 163 million cases and 3.3 million deaths have been reported worldwide.
- Inflammation is a critical factor in COVID-19 pathogenesis, with overwhelming inflammation linked to poor prognosis.
Purpose of the Study:
- To provide an overview of inflammation's role in COVID-19.
- To critically evaluate immunomodulatory and anti-inflammatory treatment strategies for COVID-19.
- To summarize key findings from existing research on COVID-19 inflammation and treatments.
Main Methods:
- Literature review of scientific studies on COVID-19, inflammation, and immune system targeting therapies.
- Critical analysis of therapeutic approaches and their efficacy.
- Synthesis of current knowledge on the subject.
Main Results:
- Inflammation plays a central role in the severity and outcomes of COVID-19.
- Various therapeutic strategies targeting the immune system and inflammation are under investigation.
- Numerous studies have explored these approaches, yielding significant insights.
Conclusions:
- Understanding the inflammatory processes in COVID-19 is crucial for developing effective treatments.
- Targeting inflammation and the immune response holds promise for managing severe COVID-19.
- Continued research is essential to refine therapeutic strategies and improve patient outcomes.
Abstract:
The coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020 by the World Health Organization (WHO). To date, there were > 163 million confirmed cases of COVID-19 and the disease has claimed > 3.3 million lives globally. As with many other diseases, inflammation is a key feature of COVID-19. When inflammation is overwhelming, it may lead to unfavorable outcomes or even death. Scientists all over the world are working tirelessly in search of therapeutic strategies to suppress or modulate inflammation in COVID-19. This review gives an overview of the role of inflammation in COVID-19. It also critically examines the various treatment approaches that target the immune system and inflammation in COVID-19, as well as highlights the key findings in the numerous studies conducted thus far.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Pneumonia II: Pathophysiology
01:30Inflammatory Response I: Vascular and Cellular
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:38Inflammation